Distributor of Diet Drug Urges Healthcare Inspectorate to Target Newspapers

Goodlife Enforcement Request Triggers Inspectorate Fines

The regulatory fallout began when the IGJ issued fines totaling tens of thousands of euros this summer to publishers of NRC, de Volkskrant, AD, and De Telegraaf. The inspectorate asserted that the publications violated the Medicines Act by running advertisements for prescription-only weight-loss drugs. However, internal records show the inspectorate did not initiate the probe against NRC independently. Instead, Goodlife’s legal representative filed an enforcement request arguing that science desk coverage breached the ban on prescription drug promotion, which stems from a 1992 European directive transposed into national law.

Commercial Competition Fueling Regulatory Scrutiny

The enforcement request from Goodlife explicitly raised concerns regarding market competition and an alleged lack of balanced reporting. The filing noted an absence of references to Mysimba in media coverage dominated by newer GLP-1 receptor agonists like semaglutide and tirzepatide. Health economist Xander Koolman of the Vrije Universiteit characterized the manufacturer’s actions as a rear-guard action. Koolman noted that historical precedents, such as the introduction of Viagra over older treatments like alprostadil, show that older therapies face intense market pressure when superior drugs become widely available.

Broad Pressures Across Dutch Media Outlets

Goodlife’s legal strategy extended beyond print journalism to television programming. Lune van der Meulen, a reporter for Nieuwsuur, stated that a distributor—identified as representing Mysimba—contacted her directly in June during a four-part series on weight-loss medication. The distributor demanded inclusion of its product and later threatened a summary injunction before backing down in August. Nieuwsuur subsequently received a separate enforcement request from Goodlife submitted to the IGJ.

Editorial Pushback and Legal Challenges

Lucas Brouwers, adjunct-hoofdredacteur of NRC, warned that publications risk being drawn into commercial disputes via regulatory bodies and confirmed the outlet will fight its 81,000-euro fine in court if maintained. Pieter Klok, hoofdredacteur of de Volkskrant, called the underlying complaint an escalation that adds arbitrariness to an already troubling restriction on vital public interest reporting.

Fines issued for illegal weight-loss drug articles

Why did the IGJ fine Dutch newspapers?

The inspectorate issued fines claiming that specific articles published by outlets like NRC and de Volkskrant constituted illegal advertising for prescription-only weight-loss drugs under the Medicines Act.

Who triggered the investigation into NRC and de Volkskrant?

Goodlife, the distributor of the weight-loss medication Mysimba, triggered the investigation by filing a formal enforcement request with the IGJ on September 29, 2025.

What are GLP-1 receptor agonists in this context?

GLP-1 receptor agonists are prescription medications that mimic natural gut hormones to signal satiety. While some are reimbursed strictly for type 2 diabetes, newer formulations are widely used for weight management.

How are the media outlets responding to the penalties?

Outlets like NRC and de Volkskrant have defended their science journalism as balanced and critical, stating they will pursue legal action to challenge the fines and protect press freedom.